Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Channa Kolb

Neurology Buffalo, NY Medical Doctor

NPI 1316176167 CMS profile 150674

100 High St, Buffalo, NY 14203

Open in the dashboard

General payments

$102,463

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Channa Kolb of Buffalo, NY is reported in the CMS Open Payments database as having received $102,463 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84 4
2024 General $1,369 56
2023 General $592 18
2022 General $10,067 13
2021 General $12,344 15
2020 General $18,971 18
2019 General $59,036 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Channa Kolb
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Channa Kolb were reported at $84. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Channa Kolb Neurology median Middle half National median
2019 $59,036 $474 $118–$2,177 $163
2020 $18,971 $367 $82–$2,309 $114
2021 $12,344 $438 $104–$2,547 $132
2022 $10,067 $442 $103–$2,388 $149
2023 $592 $464 $119–$2,312 $160
2024 $1,369 $468 $119–$2,323 $164
2025 $84 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $43,970 47 payments
  2. EMD Serono, Inc. $20,183 42 payments
  3. Alexion Pharmaceuticals, Inc. $17,565 22 payments
  4. Novartis Pharmaceuticals Corporation $16,736 43 payments
  5. Genentech USA, Inc. $3,191 24 payments
  6. Amgen Inc. $185 5 payments
  7. AbbVie, Inc. $185 9 payments
  8. ANI Pharmaceuticals, Inc. $108 4 payments
  9. Genzyme Corporation $101 3 payments
  10. Teva Pharmaceuticals USA, Inc. $55 3 payments
  11. Other $184 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $67,190 35 payments
  2. Consulting Fee $24,316 6 payments
  3. Travel and Lodging $5,686 15 payments
  4. Food and Beverage $4,948 149 payments
  5. Education $322 8 payments
Products named General payments · program years 2019–2025
  1. TECFIDERA $23,171 18 payments
  2. TYSABRI $22,320 27 payments
  3. Soliris $12,518 14 payments
  4. Mavenclad Neurology $7,615 8 payments
  5. Mavenclad Neurology $6,633 13 payments
  6. MAYZENT $5,606 11 payments
  7. PLEGRIDY $2,575 6 payments
  8. VUMERITY $2,541 4 payments
  9. AVONEX $2,480 1 payment
  10. Mavenclad Neurology $1,860 2 payments
  11. Other $2,146 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

136

Median for Neurology: 833

Drug cost

$17,530

Median for Neurology: $202,670

Branded share of claims

16.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ajovy Syringe Fremanezumab-Vfrm Brand 22 $16,318
Propranolol Hcl Generic 22 $341
Levetiracetam Generic 14 $311
Gabapentin Generic 22 $265
Donepezil Hcl Generic 33 $218
Sertraline Hcl Generic 12 $42
Memantine Hcl Generic 11 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$26,848

Medicare's payments for the services billed

Medicare patients

92

Average age 78

Services billed

267

51 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 51%
Diabetes 46%
Depression 41%
Chronic kidney disease 33%
Osteoporosis 27%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $310
$310 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $80
$80 — —
VUMERITY
  • Biogen, Inc. $64
$64 — —
QULIPTA
  • AbbVie, Inc. $50
$50 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record